Actinium

• Actinium Pharmaceuticals has enrolled the first patient in a pioneering trial evaluating Iomab-ACT as a targeted radiotherapy conditioning agent with commercial CAR-T therapy, with initial data expected in late 2025. • Iomab-ACT targets CD45 on immune cells and has shown promise in reducing serious CAR-T toxicities including ICANS and CRS, potentially addressing major barriers to CAR-T therapy access and efficacy. • The therapy could significantly expand the $4 billion CAR-T market by replacing conventional chemotherapy conditioning regimens, potentially benefiting approximately 150,000 patients diagnosed annually with eligible conditions.

Actinium Pharmaceuticals has developed ATNM-400, a novel non-PSMA targeting radiotherapy for prostate cancer using Actinium-225, achieving 99.8% tumor growth inhibition in preclinical models.

Actinium Pharmaceuticals has launched a first-of-its-kind clinical trial evaluating Actimab-A in combination with venetoclax and ASTX-727 for newly diagnosed acute myeloid leukemia patients unsuitable for intensive chemotherapy.

The FDA approved obecabtagene autoleucel (Aucatzyl) for adults with relapsed or refractory B-cell precursor ALL, marking a significant advancement in CAR T-cell therapy.

Actinium Pharmaceuticals is set to release topline data from its pivotal Phase III SIERRA trial of Iomab-B for relapsed/refractory acute myeloid leukemia (AML) in Q4 2022.

Targeted alpha therapy (TAT) is emerging as a promising cancer treatment, delivering localized radiation to tumor cells while minimizing harm to healthy tissues.

Actinium Pharmaceuticals aligned with the FDA on a Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory AML, aiming for optimized dosing and reduced trial timelines.

The SIERRA trial demonstrated that I-131 apamistamab led to a significantly higher durable complete remission rate compared to conventional care in older patients with relapsed/refractory AML.

The SIERRA trial showed that Iomab-B led to a significantly higher durable complete remission rate (17.1%) compared to conventional care (0%) in older patients with relapsed/refractory AML.

The Phase 3 SIERRA trial demonstrated that Iomab-B achieved a statistically significant durable Complete Remission (dCR) rate of 22% compared to 0% in the control arm for relapsed/refractory AML patients.